SION Overview

Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.

Wall Street analysts forecast SION stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SION is47.80 USD with a low forecast of 24.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Sionna Therapeutics Inc revenue for the last quarter amounts to -23.61M USD, increased 30.22

Sionna Therapeutics Inc. EPS for the last quarter amounts to -16830000.00 USD, increased 42.53

Sionna Therapeutics Inc (SION) has 59 emplpoyees as of May 12 2026.

Today SION has the market capitalization of 2.07B USD.